Selegiline long-term effects on brain acetylcholinesterase, (Na+,K+)-ATPase activities, antioxidant status and learning performance of aged rats

Pharmacological Research

Volumn 48, Issue 3, 2003, Pages 245-251

  Carageorgiou, Haris ^a   Zarros, Apostolos ^a   Tsakiris, Stylianos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

(Na+,K+) ATPase; Acetylcholinesterase; Aged rat brain; Learning; Selegiline; Total antioxidant status

Indexed keywords

ACETYLCHOLINESTERASE; ADENOSINE TRIPHOSPHATASE (MAGNESIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANTIOXIDANT; SELEGILINE;

AGE DISTRIBUTION; AGED; AGING; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; BRAIN HOMOGENATE; BRAIN LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; LEARNING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TASK PERFORMANCE;

EID: 0038689321     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(03)00149-X     Document Type: Article

References (51)

1. Knoll J., Ecseri Z., Kelemen K., Nievel J., Knoll B. Phenyl-isopropyl-methyl-amine (E-250), a new spectrum phychic energizer. Arch. Int. Pharmacodyn. 155:1965;154-164.
2. Ebadi M., Sharma S., Shavali S., Refaey E.H. Neuroprotective action of selegiline. J. Neurosci. Res. 67:2002;285-289.
3. Knoll J. (-)Deprenyl (selegiline): past, present, and future. Neurobiology. 8:2000;179-199.
4. Poewe W., Gerstenbrand F., Ransmayer G. Experience with selegiline in the treatment of Parkinson's disease. J. Neural Transm. 25:1987;131-135.
5. Lieberman A., Fazzini E. Experience with selegiline and levodopa in advanced Parkinson's disease. Acta Neurol. Scand. 135:1991;66-69.
6. Parkinson Study Group. Effect of tocopherol and (-)deprenyl to the progression of disability in early Parkinson's disease. New Engl J Med 1993;328:176-83.
7. Negrotti A., Bizzarri G., Calzetti S. Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study. J. Neural Transm. 108:2001;215-219.
8. Mann J.J., Aarons S.F., Wilner P.J. A controlled study of the antidepressant efficacy and side effects of (-)deprenyl. Arch. Gen. Psychiatry. 46:1989;45-50.
9. Mendlewicz J., Youdim M.B.H. L-Deprenyl, a selective monoamine oxidase type B inhibitor in the treatment of depression, a double-blind evaluation. Br. J. Psychiatry. 142:1983;508-511.
10. Knoll J. The pharmacology of selegiline ((-) deprenyl). New aspects. Scand. Suppl. 126:1989;83-91.
11. Dalló J. Effect of chronic (-)deprenyl treatment on lifespan and copulatory activity in female rats. Fundam Clin Pharmacol 1999;13(Suppl 1):148s PS96.
12. Langston S.W., Tannen C.M. Selegiline and Parkinson's disease: it's déjà vu-again. Neurology. 55:2000;1770-1771.
13. Magyar K., Haberle D. Neuroprotective and neuronal rescue effects of selegiline. Neurobiology. 7:1999;175-190.
14. +, and β-carbolinium: a microdialysis study in rats. Neurosci. Lett. 302:2001;65-68.
15. Ricci A., Mancinin M., Strocchi P., Bongrani S., Bronzetti E. Deficits in cholinergic aziridium (AF64A) in rat hippocampus: sensitivity to treatment with the monoamine oxidase-B inhibitor L-deprenyl. Drugs Exp. Clin. Res. 18:1992;163-171.
16. Carillo M.C., Kitani K., Kanai S., Sato Y., Miyasaka K., Ivy G.O. (-)Deprenyl increases activities of superoxide dismutase and catalase in certain brain regions in old male mice. Life Sci. 54:1994;975-981.
17. Cohen G., Spina M.B. (-)Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann. Neurol. 26:1981;689-690.
18. Ju W.Y.H., Holland D.P., Tatton W.G. (-)Deprenyl alters the time course of death of axotomised facial motoneurons and the hypertrophy of neighbouring astrocytes in immature rats. Exp. Neurol. 126:1994;233-246.
19. Lakshmana K.M., Shankaranarayana Rao B.S., Dhingra N.K., Ravikumar R., Govindaiah, Ramachandraet al. Chronic (-)deprenyl administration increases dendritic arborization in CA3 neurons of hippocampus and AChE activity in specific regions of the primate brain. Brain Res. 796:1998;38-44.
20. Drago F., Continella G., Spadaro F., Cavaliere S., Scapagnini F. Behavioral effects of (-)deprenyl in aged rats. Funct. Neurol. 1:1986;1165-1174.
21. Mills D., Ledger R. The effects of oral selegiline hydrochloride on learning and training in the dog: a psychobiological interpretation. Prog. Neuropsychopharmacol. Biol. Psychiatry. 8:2001;1597-1613.
22. Agnoli A., Martucci N., Fabbrini G., Buckley A.E., Fioravanti M. Monoamine oxidase and dementia: treatment with an inhibitor of MAO-B activity. Dementia. 1:1990;109-114.
23. Mangoni A., Grassi M.P., Frattola L., Piolti R., Bassi S., Motta A.et al. Effects of MAO-B inhibitor in the treatment of Alzheimer's disease. Exp. Neurol. 31:1991;100-107.
24. Piccinin G.L., Finali G.C., Picirilli M. Neuropsychological effects of L-deprenyl in Alzheimer's type dementia. Clin. Neuropharmacol. 13:1990;147-163.
25. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M.et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. New Engl. J. Med. 336:1997;1216-1222.
26. Luxenberg J.S. Review: selegiline leads to a small short term improvement in cognition and activities of daily living in Alzheimer's disease. Evid. Based Ment. Health. 5:2002;88.
27. Knoll J. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacol. Toxicol. 82:1998;57-66.
28. Wilcock G.K., Birks J., Whitehead A., Evans S.J. The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published data. Int. J. Geriatr. Psychiatry. 17:2002;175-183.
29. Frölich L. The cholinergic pathology in Alzheimer's disease - discrepancies between clinical experience and pathophysiological findings. J. Neural Transm. 109:2002;1003-1013.
30. +-ATPase activities in adult rat whole brain. Pharmacol. Res. 46:2002;165-169.
31. Committee on Care and Use of Laboratory Animals. Guide for the care and use of laboratory animals. Washington, DC: Institute of Laboratory Animal Resources, National Research Council; 1985. p. 83.
32. +-ATPase inhibition induced by free radicals. Z. Naturforsch. 55(C):2000;271-277.
33. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
34. Ellman G.L., Courtney D., Andres D., Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7:1961;88-95.
35. Bowler K., Tirri R. The temperature characteristics of synaptic membrane ATPases from immature and adult rat brain. J. Neurochem. 23:1974;611-613.
36. Dews P.B., Morse W.H. Behavioral pharmacology. Annu. Rev. Pharmacol. 1:1961;145-174.
37. Zhu J., Hamm R.J., Reeves T.M., Povlishock J.T., Phillips L.L. Postin-jury administration of L-deprenyl improves cognitive function and enhances neuroplasticity after traumatic brain injury. Exp. Neurol. 166:2000;136-152.
38. Fishman E.B., Siek G.C., MacCallum R.D., Bird E.D., Volicer L., Marqui J.K. Distribution of the molecular forms of acetylcholinesterase in human brain: alterations in dementia of the Alzheimer type. Ann. Neurol. 19:1986;246-252.
39. Dekosky S.T., Harbaugh R.E., Schmitt F.A., Bakay R.A., Chui H.C., Knopman D.S.et al. Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Intraventricular Bethanecol Study Group. Ann. Neurol. 32:1992;625-632.
40. Appleyard M.E. Acetylcholinesterase induced long-term potentiation in CA1 pyramidal cells by a mechanism dependent on metabotropic glutamate receptors. Neurosci. Lett. 190:1995;25-28.
41. +-ATPase and acetylcholinesterase in postnatally developing rat brain. Med. Sci. Res. 24:1996;155-156.
42. +-ATPase activity and acetylcholine release in rat cortical synaptosomes. J. Neurochem. 36:1981;467-475.
43. Tsakiris S., Angelogianni P., Schulpis K.H., Stavridis J.C. Protective effect of L-phenylalanine on rat brain acetylcholinesterase inhibition induced by free radicals. Clin. Biochem. 33:2000;103-106.
44. +)-adenosine triphosphatase regulation by the sympathetic nervous system: effects of noradrenergic stimulation and lesion in vivo. J. Pharmacol. Exp. Ther. 228:1984;304-311.
45. Bogdanski D.F., Tissuri A., Brodie B.B. Role of sodium, potassium, ouabain and reserpine in uptake, storage and metabolism of biogenic amines in synaptosomes. Life Sci. 7:1968;419-428.
46. Herrero J.R., Aragon M.C., Gimenez C., Valdieso F. Inhibition by L-phenylalanine of tryptophan transport by synaptosomal plasma membrane vesicles: implications in the pathogenesis of phenylketonuria. J. Inherit. Metab. Dis. 6:1983;32-35.
47. +-ATPase activity possibly regulated by a specific serotonin receptor. Brain Res. 408:1987;399-402.
48. +-ATPase inhibitors. Can. J. Physiol. Pharmacol. 55:1977;170-180.
49. Mata M., Fink D.J., Gainer H., Smith C.B., Davidsen L., Savakis H.et al. Activity dependent energy metabolism in rat posterior pituitary primarily reflects sodium pump activity. J. Neurochem. 34:1980;213-215.
50. Ischiropoulos H., Duran D., Horwitz J. Peroxynitrite-mediated inhibition of DOPA synthesis in PC12 cells. J. Neurochem. 65:1995;2366-2372.
51. Themann C., Alvarez Fischer D., Gross S., Westermann R., Weihe E., Kuschinsky K.et al. Effect of repeated treatment with high doses of selegiline on behavior striatal dopaminergic transmission and tyrosine hydroxylase mRNA levels. Naunyn Schmiedebergs Arch. Pharmacol. 365:2002;22-28.